9.0158
price down icon0.83%   -0.0742
 
loading
Schlusskurs vom Vortag:
$9.09
Offen:
$9.09
24-Stunden-Volumen:
94,402
Relative Volume:
0.05
Marktkapitalisierung:
$1.42B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-6.6784
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+8.22%
1M Leistung:
+23.49%
6M Leistung:
+8.22%
1J Leistung:
+37.42%
1-Tages-Spanne:
Value
$8.96
$9.145
1-Wochen-Bereich:
Value
$8.03
$9.53
52-Wochen-Spanne:
Value
$5.80
$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name
Firmenname
Ocular Therapeutix Inc
Name
Telefon
781-357-4000
Name
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Name
Mitarbeiter
274
Name
Twitter
@OCUTX
Name
Nächster Verdiensttermin
2025-03-03
Name
Neueste SEC-Einreichungen
Name
OCUL's Discussions on Twitter

Vergleichen Sie OCUL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
OCUL
Ocular Therapeutix Inc
9.015 1.42B 61.10M -138.36M -90.59M -1.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.56 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.58 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.56 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.72 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
264.94 28.51B 3.81B -644.79M -669.77M -6.24

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet William Blair Outperform
2025-03-18 Eingeleitet RBC Capital Mkts Outperform
2025-03-11 Eingeleitet Needham Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-06-20 Hochstufung TD Cowen Hold → Buy
2024-05-31 Fortgesetzt Piper Sandler Overweight
2024-02-09 Eingeleitet BofA Securities Buy
2023-04-21 Eingeleitet Robert W. Baird Outperform
2022-08-10 Fortgesetzt Berenberg Buy
2021-08-10 Hochstufung H.C. Wainwright Neutral → Buy
2020-12-28 Herabstufung H.C. Wainwright Buy → Neutral
2020-12-17 Eingeleitet Berenberg Buy
2020-11-13 Bestätigt Raymond James Strong Buy
2020-08-10 Bestätigt H.C. Wainwright Buy
2020-03-03 Hochstufung Raymond James Outperform → Strong Buy
2019-05-21 Herabstufung Cowen Outperform → Market Perform
2019-05-21 Bestätigt H.C. Wainwright Buy
2019-05-21 Herabstufung Raymond James Strong Buy → Outperform
2018-12-03 Bestätigt Cantor Fitzgerald Overweight
2018-11-15 Eingeleitet Raymond James Strong Buy
2018-09-07 Eingeleitet Piper Jaffray Overweight
2017-10-24 Eingeleitet Guggenheim Buy
2017-07-26 Eingeleitet H.C. Wainwright Buy
2017-07-12 Bestätigt Cantor Fitzgerald Overweight
2017-06-23 Herabstufung Morgan Stanley Overweight → Equal-Weight
2017-02-10 Eingeleitet Cantor Fitzgerald Overweight
2016-11-15 Bestätigt RBC Capital Mkts Outperform
2016-08-11 Eingeleitet JMP Securities Mkt Outperform
2016-02-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2015-10-23 Herabstufung Morgan Stanley Overweight → Equal-Weight
2015-08-13 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten

pulisher
Jun 18, 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025 - Ophthalmology Times

Jun 18, 2025
pulisher
Jun 17, 2025

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade) (OCUL) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 | OCUL Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocular Therapeutix, Inc. to Present Clinical Trial Results and Insights at Summit 2025 in Las Vegas - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Breakthrough Eye Disease Treatment Data: Ocular Therapeutix Reveals Clinical Trial Results at CTS 2025 - Stock Titan

Jun 16, 2025
pulisher
Jun 11, 2025

Ocular Therapeutix Approves Key Amendments at Annual Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology - insights.citeline.com

Jun 11, 2025
pulisher
Jun 10, 2025

Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors - simplywall.st

Jun 10, 2025
pulisher
Jun 06, 2025

Trading (OCUL) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

What is HC Wainwright’s Forecast for OCUL Q1 Earnings? - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN

Jun 01, 2025
pulisher
May 30, 2025

Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright - Defense World

May 30, 2025
pulisher
May 30, 2025

Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 30, 2025
pulisher
May 30, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World

May 30, 2025
pulisher
May 29, 2025

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga

May 29, 2025
pulisher
May 29, 2025

Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st

May 29, 2025
pulisher
May 28, 2025

Sector Update: Health Care - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Ocular stock gains after wet AMD trial update (OCUL:NASDAQ) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix chief scientific officer sells $21,712 in stock - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix (OCUL) Concludes Enrollment for Key Retinal T - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix™ To Close Enrollment This Week for - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration | OCUL Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Ocular Therapeutix chief scientific officer sells $21,712 in stock By Investing.com - Investing.com Canada

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $755,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 28, 2025
pulisher
May 28, 2025

D. E. Shaw & Co. Inc. Takes $268,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 28, 2025
pulisher
May 27, 2025

Ocular Therapeutix Executives Sell Shares to Cover Tax Obligations - TradingView

May 27, 2025
pulisher
May 27, 2025

Ocular Therapeutix at Stifel 2025 Forum: Eyeing a Disruptive Future By Investing.com - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

(OCUL) Trading Report - news.stocktradersdaily.com

May 27, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 24, 2025
pulisher
May 21, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

May 21, 2025
pulisher
May 20, 2025

Ocular Therapeutix at BioConnect: Strategic Advances in Wet AMD Treatment By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 17, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp - Defense World

May 17, 2025
pulisher
May 14, 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Ocular Therapeutix CEO to Present at RBC, Mizuho, and Top Healthcare Conferences: Key Dates for Investors - Stock Titan

May 14, 2025
pulisher
May 14, 2025

The Manufacturers Life Insurance Company Sells 2,399 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 14, 2025
pulisher
May 13, 2025

Transcript : Ocular Therapeutix, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Hsbc Holdings PLC Buys 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 12, 2025
pulisher
May 11, 2025

Tower Research Capital LLC TRC Has $76,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 11, 2025
pulisher
May 09, 2025

HC Wainwright Analysts Reduce Earnings Estimates for OCUL - Defense World

May 09, 2025
pulisher
May 09, 2025

William Blair Brokers Decrease Earnings Estimates for OCUL - Defense World

May 09, 2025
pulisher
May 08, 2025

Analysts Offer Predictions for OCUL FY2026 Earnings - Defense World

May 08, 2025

Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.45
price down icon 1.49%
$35.99
price down icon 0.29%
$20.75
price down icon 0.48%
$106.44
price up icon 0.30%
$103.92
price down icon 1.26%
biotechnology ONC
$265.46
price down icon 0.24%
Kapitalisierung:     |  Volumen (24h):